Puma Biotechnology Total Liabilities

Puma Biotechnology (PBYI) currently reports a total liabilities of $54M as of June 2026. That compares with $90M in the prior-year period — down 39.9% year over year. Use the charts on this page to explore Puma Biotechnology's total liabilities history and peer comparisons.

Puma Biotechnology's total liabilities decreased from $90M to $54M — a 39.9% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Puma Biotechnology reported $54M in total liabilities as of June 2026. That compares with $90M in the prior-year period — down 39.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $54M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Puma Biotechnology, and consider following PBYI for alerts when major investors trade the stock.

Puma Biotechnology is classified in the Healthcare sector. On total liabilities, it currently shows $54M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PBYI with unrelated industries.